Biomerica, Inc. (BMRA) EPS Estimated At $-0.03

January 8, 2018 - By Winifred Garcia

 Biomerica, Inc. (BMRA) EPS Estimated At $ 0.03
Investors sentiment increased to 0.25 in 2017 Q3. Its up 0.25, from 0 in 2017Q2. It is positive, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 66,682 shares or 11.38% less from 75,249 shares in 2017Q2 were reported.
Wells Fargo & Mn holds 6,500 shares or 0% of its portfolio. Millennium Mgmt Ltd Liability Com holds 27,023 shares. Malaga Cove Cap Limited Company holds 0.03% in Biomerica, Inc. (NASDAQ:BMRA) or 19,000 shares. Panagora Asset Management Inc holds 0% or 10,077 shares in its portfolio. 250 were accumulated by North Star Invest Mngmt Corp. Bancorporation Of America De accumulated 3,832 shares.

Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report $-0.03 EPS on January, 16.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.02 EPS previously, Biomerica, Inc.’s analysts see 50.00 % EPS growth. The stock increased 6.47% or $0.2699 during the last trading session, reaching $4.4399. About 39,406 shares traded or 119.48% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since January 8, 2017 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $37.87 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Marketwatch.com which released: “Biomerica Inc.” on April 19, 2011, also Globenewswire.com with their article: “Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test” published on September 12, 2017, Seekingalpha.com published: “Biomerica: The Next Major IBS Product” on September 02, 2016. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Marketwired.com and their article: “Biomerica Announces Year End Results” published on August 30, 2016 as well as Marketwired.com‘s news article titled: “Biomerica Signs Exclusive License Agreement for Korean Market With Total Value …” with publication date: May 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>